• Title/Summary/Keyword: Non-pharmaceutical treatment

Search Result 184, Processing Time 0.027 seconds

Involvement of Proinflammatory Cascades in Nitrosative Damage in PC12 Cells

  • Um, So-Young;Jang, Jung-Hee;Na, Hye-Kyung;Surh, Young-Joon
    • Proceedings of the PSK Conference
    • /
    • 2002.10a
    • /
    • pp.324.2-325
    • /
    • 2002
  • Recent studies suggest that inflammatory events are implicated in a variety of human diseases including cancer and neurodegenerative diseases. and non-steroidal anti-inflammatory drugs have beneficial effects in treatment or prevention of these disorders. It has been reported that expression of cyclooxygenase (COX)-2 and nitric oxide synthase and subsequent production of prostaglandin (PG) and nitric oxide (NO). respectively are elevated in many inflammatory disorders. (omitted)

  • PDF

Antiretroviral Therapy 2000

  • Samuel, Rafik;Suh, Byungse
    • Archives of Pharmacal Research
    • /
    • v.23 no.5
    • /
    • pp.425-437
    • /
    • 2000
  • As we enter the new millennium, there have been dramatic improvements in the care of patients with HIV infection. These have prolonged life and decreased morbidity and mortality. There are fourteen currently available antiretrovirals approved in the United States for the treatment of this infection. The medications, including their pharmacokinetic properties, side effects, and dosing are reviewed. In addition, the current approach to the use of these medicines is discussed.

  • PDF

PK/PD Modeling for Glucose-lowering Effect of Metformin in Korean Volunteers

  • Lee, Shin-Hwa;Yun, Min-Hyuk;Kwon, Kwang-Il
    • Proceedings of the PSK Conference
    • /
    • 2003.04a
    • /
    • pp.307.1-307.1
    • /
    • 2003
  • Metfotrmin is a biguanide antihyperglycemic agent often used for the treatment of non-insulin dependent diabetics(NIDDM). Metformin lowers both fasting and postprandial plasma glucose concentrations by improving insulin sensitivity at hepatic and peripheral tissues. The pharmacokinetics and pharmacodynamics of metformin were studied in Korean healthy volunteers at fasting state over 10 hours. (omitted)

  • PDF

Celecoxib Attenuates Nitric Oxide-Induced Apoptosis in PC12 Cells by Inhibiting AP-1 Activation and COX-2 Expression.

  • Li, Mei-Hua;Jang, Jung-Hee;Surh, Young-Joon
    • Proceedings of the PSK Conference
    • /
    • 2003.10b
    • /
    • pp.143.2-144
    • /
    • 2003
  • Recent studies suggest that inflammatory events are implicated in a variety of ailments such as cancer and neurodegenerative diseases, and certain non-steroidal anti-inflammatory drugs have beneficial effects for the treatment or prevention of these disorders. Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the prostaglandin (PG) synthesis, is induced by various pro-inflammatory stimuli including nitric oxide (NO) and has been reported to cause and/or aggravate neuronal cell death. (omitted)

  • PDF

Bitam-S Improves the Non-alcoholic Fatty Liver Disease in C57BL/6J ob/ob Mice (Ob/ob Mouse에서 비탐-에스의 비 알코올성 지방간 개선 활성)

  • Han, Eun-Jung;Kim, Ae-Kyung;Chung, Sung-Hyun
    • YAKHAK HOEJI
    • /
    • v.49 no.4
    • /
    • pp.306-311
    • /
    • 2005
  • Semisulospira libertine (SL) has been used as a folk medicine for quenching a thirst, hepatic fever and inflammation in oriental countries. Although SL has been anecdotally ascertained to ameliorate the hepatic diseases, there are no sufficient experimental evidences. The purpose of this study was to examine the effect of Bitam-S, in which SL is a main component, on non-alcoholic fatty liver disease manifested in C57BL/6J ob/ob mice. At 6 week old, the ob/ob mice were randomly divided into four groups; control and three treatment groups. The control mice was to receive a regular diet, and the treatment groups were fed a regular diet with either 250mg/kg, 500mg/kg of Bitam-S (BS250 and BS500) or 300mg/kg of metformin (MT300) for a 8-week period. Bitam-S exerted beneficial effects on lipid homeostasis in ob/ob mice that are not necessarily due to its ability to decrease food intake but its specific effects on hepatic lipogenesis related genes (SREBP1a, FAS and SCD-1). The combined effects of Bitam-S to reduce body weight and lipogenic gene expressions, and reduce the deposition of triglyceride in the liver are indicative of a marked improvement in obesity-related non-alcoholic fatty liver disease. Taken together, Bitam-S has potential as a treatment agent for non-alcoholic fatty liver disease and deserves clinical trial in the near future.

Stilbenes contribute to the anticancer effects of Rheum undulatum L. through activation of apoptosis

  • Tuy An Trinh;Dahae Lee;Seonju Park;Seung Hyun Kim;Jae Gyu Park;Ji Hwan Kim;Ki Sung Kang
    • Oncology Letters
    • /
    • v.17 no.3
    • /
    • pp.2953-2959
    • /
    • 2019
  • Rheum undulatum L. (R. undulatum) is a medicinal plant used for the treatment of inflammatory diseases in East Asian countries. Numerous stilbenes isolated from R. undulatum have been revealed to possess anticancer effects. The aim of the present study was to evaluate the effect of extracts and compounds isolated from R. undulatum on human gastric cancer cell viability and to elucidate their molecular mechanism of action on the apoptosis pathway. The results demonstrated that aloe-emodin and chrysophanol 1-O-β-D-glucopyranoside, isolated from the methanolic extract of dried rhizomes of R. undulatum, exhibited anti-proliferative effects on the human gastric carcinoma cell line AGS, with IC50 values of 84.66±0.44 and 68.28±0.29 µM, respectively. The percentage of apoptotic cells increased significantly following treatment with each compound at a concentration of 100 µM, compared with that in the non-treated group in the image-based cytometry assay. Western blot analysis revealed that these compounds activated the caspase cascade and inhibited B-cell lymphoma-2, an anti-apoptotic protein.

Reduction of Hepatic Glutathione by Acute Taurine Treatment in Male Mice (숫컷 생쥐에서 타우린 투여에 의한 간내 글루타치온의 감소)

  • 이선영;곽혜은;김영철
    • YAKHAK HOEJI
    • /
    • v.47 no.4
    • /
    • pp.218-223
    • /
    • 2003
  • Effect of taurine treatment on metabolism of glutathione (GSH) was studied in adult male ICR mice. An acute injection of taurine (250 mg/kg, ip) resulted in a significant decline of hepatic GSH level at t = 6 hr, but plasma GSH level was not altered. The activity of GSH-related enzyme in liver, such as GSH peroxidase, GSSG reductase, GSH S-transferases, ${\gamma}$-glutamylcysteine synthetase or ${\gamma}$-glutamyltranspeptidase, was not affected by taurine at t = 2.5 or 6 hr. Plasma cysteine and cystine levels were elevated rapidly following taurine treatment. Hepatic cysteine level was decreased by taurine, reaching a level approximately 70% of control at t = 4 and 6 hr. In conclusion, the results indicate that an acute dose of taurine decreases hepatic GSH level by reducing the availability of cysteine, an essential substrate for synthesis of this tripeptide in liver. It is also suggested that taurine may decrease the cysteine uptake by competing with this S-amino acid for a non-specific amino acid transporter.

Assessing the Effectiveness and Safety of Direct-acting Antiviral Treatment in Korean Patients with Hepatitis C Virus Genotype 1b or 2 at a Tertiary Care Hospital

  • Park, Mi Seon;Yang, Young-Mo;Park, Ki Hyun;Yoon, Hyonok;Kim, Ju Sin;Choi, Eun Joo
    • Korean Journal of Clinical Pharmacy
    • /
    • v.32 no.3
    • /
    • pp.191-203
    • /
    • 2022
  • Background: Direct-acting antivirals are recommended for the treatment of chronic hepatitis C virus in Korea. However, evaluation of direct-acting antiviral regimens in a real-world setting is limited. The aims of this study were to investigate the effectiveness and safety of direct-acting antiviral treatment in Korean patients infected with chronic hepatitis C virus genotype 1b or 2 at a tertiary care hospital. Methods: This was a retrospective study conducted with patient data obtained between August 2015 and August 2019 at Jeonbuk National University Hospital. The primary effectiveness endpoint was sustained virological response 12 weeks post-treatment (SVR12) via intention-to-treat (ITT) and modified intention-to-treat (mITT) analyses. Results: Of the 270 patients, 47.0% were infected with genotype 1b and 53.0% with genotype 2. ITT analysis revealed that SVR12 was achieved in 78.9% of all patients, 77.2% in genotype 1b patients, and 80.4% in genotype 2 patients. Of the 21.1% of all patients who did not achieve SVR12, the majority of treatment failures were non-virologic failures (19.7%). mITT analysis revealed that SVR12 was achieved in 98.2% of all patients, 98.0% in genotype 1b patients, and 98.3% in genotype 2 patients. Almost half of all patients experienced one or more adverse events (43.3%), leading to 2.6% discontinuing scheduled treatment. The most common adverse event was anemia. Conclusions: Direct-acting antiviral-based treatment regimens showed high effectiveness and safety. Non-virological factors, such as premature treatment discontinuation due to adverse events or loss of follow-up, were the major disruptors in achieving SVR12.

Prolonged Gene Expression Following Erythrocyte-Mediated Delivery of TRAIL Plasmid DNA (혈구세포 수송체로 투여된 트레일 유전자의 혈중 발현 지속 효과)

  • Byun, Hyang-Min;Kwon, Kyoung-Ae;Shin, Jee-Young;Oh, Yu-Kyoung
    • Journal of Pharmaceutical Investigation
    • /
    • v.33 no.4
    • /
    • pp.261-265
    • /
    • 2003
  • Tumor necrosis facto-related apoptosis-inducing ligand (TRAIL) is a recently identified member of the tumor necrosis factor cytokine superfamily. TRAIL has been shown to induce apoptosis in a number of tumor cells whereas cells from most of normal tissues are highly resistant to TRAIL-induced apoptosis. These observations have raised considerable interest in the use of TRAIL in tumor therapy. In this study we report the biodistribution fates and serum expression pattern of plasmid DNA encoding TRAIL (pTRAIL) delivered in erythrocyte ghosts (EG). pTRAIL was loaded into EG by electroportion in a hypotonic medium The mRNA expression of pTRAIL was prolonged following delivery in EG-encapsulated forms. EG containing pTRAIL showed significant levels of mRNA expression in the blood over 9 days. The organ expression patterns of pTRAIL delivered via EG, however, did not significantly differ from those of naked pTRAIL, indicating that the expression-enhancing effect of EG containing pTRAIL was localized to the blood. These results suggest that pTRAIL-loaded EG might be of potential use in the treatment of hematological diseases such as TRAIL-sensitive leukemia.